• Anti-commons: Numerous claimants to IP on research tools lead to breakdown and loss of collective surplus, impeding development & commercialization of promising therapeutics • Limitations on subsequent discovery and improvement due to restricted access to patented upstream, foundational discoveries • Project goal: to explore the degree to which these concerns have materialized. • Concern over patent scope -Reach through-COX-2 (U. of Rochester) was a concern, but now diminished with the federal court decision 6 Anti-Commons "tragedies"?
• Breakdowns: Vast majority of respondents (over 90%) say "Never happens" • Licensing fees for tools -Have risen -Not a problem for larger firms, but can challenge smaller firms and universities -Also, patent holders often price discriminate • But remember:
-Patents key to incentives to discover new tools -Even at a price, tools increase R&D productivity
